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Abstract 
Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Pathologically, 
PAH is characterised by sustained vasoconstriction and progressive obliteration of 
small pulmonary arteries through a process of medial thickening, intimal fibrosis and 
the formation of angioproliferative lesions. Current treatments target the sustained 
vasoconstriction via either the prostacyclin, endothelin or nitric oxide pathway but do 
little to address the underlying progressive proliferative vascular disease. 
Dysregulated expression of microRNA (miR) has been identified in PAH and we have 
recently highlighted reduced miR-140-5p in patients with PAH. Replacement of miR-
140-5p attenuated disease in animal models with the regulation of Smurf1, a E3 
ubiquitin ligase targeting BMPR2 as one identified mechanism. These data highlight 
Smurf1 inhibition as a treatment for PAH.   
 
 
 
Editorial 
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised 
by occlusive remodelling of the small pulmonary arteries within the lung. The 
complex pathology of PAH is characterised by sustained pulmonary vasoconstriction, 
early pulmonary artery endothelial cell (PAEC) dysfunction/leak, proliferation of 
pulmonary artery smooth muscle (PASMC), emergence of apoptosis resistance 
PAEC and the recruitment of circulating inflammatory cells [1]. Untreated, the 
disease carries a median life expectancy of less than 3 years [2]. Current 
pharmacological treatments are primarily vasodilators, as their mechanism of action 
and offer a significant increase in survival but there remains no cure other than 
transplantation.  
 
Since the identification of mutations in the gene encoding bone morphogenetic 
protein receptor type 2 (BMPR2) in familial cases of PAH over 15 years ago [3], there 
are now well-established additional mechanistic insights into disease pathogenesis 
including interaction with growth factors including PDGF, serotonin pathway, 
inflammation including, IL-6 [4,5], TNF superfamily members osteoprotegerin [6-8]  
and TRAIL[9,10], mitochondria metabolism, oestrogen as well as epigenetic 
regulation of these pathways [1,11]. BMPR2 mutations are estimated to be present in 
up to 80% of patients with heritable PAH and 30% of Idiopathic PAH, and confer a 
worse prognosis [12] but penetrance of disease in mutation carriers is low. 
Subsequently, the precise cell and molecular mechanisms leading to disease 
manifestation, and driving pathogenesis remain poorly understood. Dissecting the 
molecular mechanisms underlying PAH is therefore crucial if effective treatments for 
a condition that has a worse prognosis than many malignancies need to be 
developed. 
 
The dysregulation of a number of microRNA (miR) has been identified in both 
patients with PAH, and investigated in animal models of the disease [13]. Several of 
these miR provide mechanistic insight [14] and prognostic utility [15] but discordance 
between models and clinical samples have reported [16].  
 
We have recently published our research describing reduced levels of miR-140-5p in 
patients with PAH, and animal models of PAH [17]. Whole blood expression of miR-
140-5p correlated with clinical measures of disease severity, and predicted survival. 
To determine whether miR-140-5p was important in disease progression, or merely a 
bystander we performed a series of pre-clinical studies where we delivered synthetic 
miR-140-5p packaged within liposomes nebulised directly to the lung. We first looked 
at whether prophylactic treatment concurrent with disease initiation, followed by 
therapeutic administration in rats where disease was first allowed to manifest utilising 
two rat models. In all cases rats treated with the miR-140-5p and demonstrated a 
significant attenuation of disease phenotype compared to those treated with a 
scrambled miR sequence. The benefit on disease phenotype was observed in both a 
reduction in haemodynamic indices of PAH and a reduction in the severity of 
pulmonary vascular remodelling. 
 
Bioinformatic prediction of miR-140-5p targets identified an overrepresentation of 
TGF beta and BMP signalling related mRNA including several important genes 
previously associated with PAH including the PDGFalpha receptor and VEGF. The 
most connected target within this network, and the one with the most conserved miR-
140-5p binding site was Smurf1 mRNA.  Smurf1 is a E3 ubiquitin ligase that targets 
type I BMP receptors (including BMPR2 [18]) and downstream signalling mediators 
[19] for ubiquitination and degradation. Through these actions Smurf1 acts a 
negative regulator of BMPR2 signalling. We therefore sought to determine whether 
one of the mechanisms by which miR-140-5p regulates PAH pathogenesis was via 
Smurf1. In lung tissue from miR-140-5p and control animals we demonstrated that 
there was an inverse correlation between levels of miR-140-5p and Smurf1. Further 
increasing confidence that Smurf1 is important in human disease examination of 
explanted lung tissue from patients with idiopathic and heritable PAH demonstrated 
increased expression of Smurf1 within the pulmonary vasculature. A miR can 
UHJXODWHWDUJHWP51$WKURXJKGLUHFWWDUJHWLQJRIWKH¶XQWUDQVFULEHGUHJLRQRUQRQ-
direct mechanisms. To demonstrate that the Smurf1 ¶ XQWUanscribed region is 
regulated by binding miR-140-5p directly we modulated expression a reporter 
construct with a luciferase gene upstream of the Smurf1 ¶875 E\ FR-transfection 
with miR-140-5p mimic and inhibitor in human PASMC. We also demonstrated 
augmentation of BMP signalling with miR-140-5p mimic and SMURF1 inhibition 
(siRNA) in PASMC by modulation of expression of a BMP response element 
luciferase construct (ID1 promoter).  
 
These experiments demonstrated that miR-140-5p is reduced in PAH and that it acts 
directly on Smurf1 to modulate BMP signalling in a disease relevant cell type. To 
determine the role of Smurf11 on the development of PAH we induced disease in 
C57BL6 mice. Deletion of Smurf1 provided an allele dependent protection from the 
development of disease, with appropriate reduction in right ventricular hypertrophy 
and remodelling of the small vessels of the pulmonary arterial system.  
 
The first therapy targeting the ubiquitin proteasome pathway, Bortezomib a 
proteasome inhibitor, was approved by the FDA in 2003 yet no further therapies 
targeting other aspects of the ubiquitin proteasome pathway have emerged.  Despite 
the promise afforded by Bortezomib, in part due to complex structural diversity, 
complex mechanisms of regulation and unknowns in translating biochemical activity 
to functional cellular effect on disease-relevant mechanisms, significant barriers in 
targeting other components of the proteasome pathway, notably E3 ligases still 
remain. The HECT family members of E3 ligases such as Smurf1 typically 
demonstrate a higher degree of catalytic activity than other E3 ligase families 
suggesting the potential to exploit conventional enzyme inhibitor mechanisms to 
block substrate ubiquitination [20]. In the context of therapeutic value for PAH 
patients, an inhibitor for Smurf1 is highly attractive whereby ubiquitination of key 
substrates within the BMP pathway such as BMPR2 may be inhibited restoring 
signalling through this key pathway [17]. Compared to a therapeutic miR140-5p 
mimetic, an inhibitor of Smurf1 may be more tractable where challenges such as 
rapid miR degradation, low cellular penetration and target engagement particularly in 
complex remodelled pulmonary vasculature of PAH patients and potential for liver 
toxicity with miR therapeutics all may limit ability to progress promising molecules to 
the clinic and ultimately represent barriers to achieving clinical efficacy.  Although 
Smurf1 is reported to have up to 89 different protein substrates [21] suggesting a 
complex network of pathways may be modulated by a Smurf1 inhibitor, such 
pathway interactions are anticipated to be context- and location dependent with 
Smurf1 protein being enhanced in selected cell types by specific disease stimuli as 
evident from immunohistochemistry performed on lung tissue from PAH patients. 
Additionally, the number of potential pathways modulated by a Smurf1 inhibitor are 
ultimately represent a smaller subset of pathways that targeting miR140-5p which in 
addition to Smurf1, also regulates expression of PDGFR and ALK5. Together, these 
data suggest that a selective Smurf1 inhibitor may be a suitable novel therapy for 
PAH. 
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